Newsroom
201 Therapeutics receives CHF 40,000 from Venture Kick to advance liver cancer therapy commercialization
26.05.2026
201 Therapeutics receives CHF 40,000 from Venture Kick to advance its oral small-molecule therapies for hepatocellular carcinoma. By directly targeting and eliminating liver cancer cells while sparing healthy tissue, the company aims to add ... En savoir plus
Biodelphis Therapeutics receives CHF 150,000 from Venture Kick to advance targeted therapies for difficult-to-treat cancers
22.05.2026
The EPFL spin-off Biodelphis Therapeutics has obtained CHF 150,000 from Venture Kick to develop a new generation of targeted therapies for cancers that do not respond well to existing treatments. The biotech startup aims to improve treatmen ... En savoir plus
HAYA Therapeutics starts clinical trial for heart disease therapy
20.05.2026
Swiss biotech company HAYA Therapeutics has reached a new milestone as it officially entered the clinical stage with the dosing of the first cohort in its Phase 1 trial for HTX-001, an investigational therapy targeting cardiac fibrosis in p ... En savoir plus
Archive Newsletter
Spring momentum across Swiss startups 🌱
A record 2025, and kicking bigger in 2026! 🚀
Kicking Finish, Bold Outlook✨
Communiqués de Presse
Press review
1000 Unternehmen mit Venture Kick gegründet
Contact medias
Pour toute question ou demande médias, veuillez envoyer un email à notre équipe de communication. Si vous avez une question d’ordre général sur Venture Kick, veuillez voir notre page contact.
Vous pouvez obtenir davantage d’informations sur Venture Kick ici ou télécharger le rapport annuel ici.